Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert E Reiter

Showing results (1-10 of 219) with videos related to

Pageof 22
Sort By:
Urologic Oncology|March 17, 2009
The urologist role in basic and clinical translational research: Personal reflections of a urologic scientistRobert E Reiter
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|August 18, 2016
Risk stratification of prostate cancer 2016Robert E Reiter
European Urology|June 14, 2016
Is Targeted Biopsy Applicable to Patients on Active Surveillance?Kris Prado, Robert E Reiter
Nature Clinical Practice. Urology|February 14, 2006
What are the operating characteristics of PSA screening for prostate cancer?Robert E Reiter, Benjamin Shurtleff
Nature Clinical Practice. Urology|October 24, 2007
What factors affect the PSA relapse-free survival times in patients treated with permanent seed brachytherapy?Robert E Reiter, Stephen Riggs
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2017
Why Targeting PSMA Is a Game Changer in the Management of Prostate CancerNicholas M Donin, Robert E Reiter
Current Opinion in Urology|March 3, 2015
Risk stratification of prostate cancer in the modern eraAndrew S Behesnilian, Robert E Reiter
Current Opinion in Urology|August 13, 2002
Role of prostate stem cell antigen in prostate cancer researchMark W Jalkut, Robert E Reiter
Clinical Prostate Cancer|January 8, 2005
Molecular markers and prostate cancer prognosisJonathan L Chin, Robert E Reiter
Translational Andrology and Urology|July 21, 2017
Multi-parametric magnetic resonance imaging as a management decision toolDavid C Johnson, Robert E Reiter
Pageof 22

Showing results (1-10 of 219) with videos related to

Sort By:
Pageof 22
Urologic Oncology|March 17, 2009
The urologist role in basic and clinical translational research: Personal reflections of a urologic scientistRobert E Reiter
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|August 18, 2016
Risk stratification of prostate cancer 2016Robert E Reiter
European Urology|June 14, 2016
Is Targeted Biopsy Applicable to Patients on Active Surveillance?Kris Prado, Robert E Reiter
Nature Clinical Practice. Urology|February 14, 2006
What are the operating characteristics of PSA screening for prostate cancer?Robert E Reiter, Benjamin Shurtleff
Nature Clinical Practice. Urology|October 24, 2007
What factors affect the PSA relapse-free survival times in patients treated with permanent seed brachytherapy?Robert E Reiter, Stephen Riggs
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2017
Why Targeting PSMA Is a Game Changer in the Management of Prostate CancerNicholas M Donin, Robert E Reiter
Current Opinion in Urology|March 3, 2015
Risk stratification of prostate cancer in the modern eraAndrew S Behesnilian, Robert E Reiter
Current Opinion in Urology|August 13, 2002
Role of prostate stem cell antigen in prostate cancer researchMark W Jalkut, Robert E Reiter
Clinical Prostate Cancer|January 8, 2005
Molecular markers and prostate cancer prognosisJonathan L Chin, Robert E Reiter
Translational Andrology and Urology|July 21, 2017
Multi-parametric magnetic resonance imaging as a management decision toolDavid C Johnson, Robert E Reiter
Pageof 22